IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution

Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with IDH1 and IDH2 (IDH1/2) mutations are ongoing. Reports of IDH1/2‐mutated non–small cell lung cancers (NSCLCs), however, are limited.

[1]  J. Eshleman,et al.  Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens. , 2019, American journal of clinical pathology.

[2]  P. Wen,et al.  Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors , 2019, Investigational New Drugs.

[3]  Yanjun Wang,et al.  IDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5 , 2018, Royal Society Open Biology.

[4]  Lisa M Haley,et al.  Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers. , 2018, Archives of pathology & laboratory medicine.

[5]  L. Tafe,et al.  Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations. , 2018, Human pathology.

[6]  R. Collins,et al.  Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.

[7]  D. Aisner,et al.  Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[8]  A. Bode,et al.  IDH2 is a novel diagnostic and prognostic serum biomarker for non‐small‐cell lung cancer , 2018, Molecular oncology.

[9]  M. Mikuła,et al.  IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma , 2018, Journal of Cancer.

[10]  Robyn L. Temple-Smolkin,et al.  Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. , 2018, Archives of pathology & laboratory medicine.

[11]  J. Townsend,et al.  Effect Sizes of Somatic Mutations in Cancer , 2017, bioRxiv.

[12]  K. Rabe,et al.  Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. , 2017, The New England journal of medicine.

[13]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[14]  Lisa M Haley,et al.  Clinical mutational profiling of 1006 lung cancers by next generation sequencing , 2017, Oncotarget.

[15]  Nicolai J. Birkbak,et al.  Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[16]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[17]  A. Bode,et al.  A new functional IDH2 genetic variant is associated with the risk of lung cancer , 2017, Molecular carcinogenesis.

[18]  N. McGranahan,et al.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.

[19]  Steven M. Chan,et al.  Isocitrate dehydrogenase mutations in myeloid malignancies , 2016, Leukemia.

[20]  J. Eshleman,et al.  Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next‐generation sequencing , 2016, Cancer cytopathology.

[21]  K. Yen,et al.  IDH mutations in cancer and progress toward development of targeted therapeutics. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  P. Illei,et al.  CDX-2 Expression in Primary Lung Adenocarcinoma , 2016, Applied immunohistochemistry & molecular morphology : AIMM.

[23]  Lisa M Haley,et al.  Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers , 2015, Modern Pathology.

[24]  M. Ge,et al.  Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies , 2015, Oncotarget.

[25]  Nicolai J. Birkbak,et al.  Clonal status of actionable driver events and the timing of mutational processes in cancer evolution , 2015, Science Translational Medicine.

[26]  Tomas Radivoyevitch,et al.  The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. , 2014, Biochimica et biophysica acta.

[27]  J. Eshleman,et al.  Cytosine Deamination Is a Major Cause of Baseline Noise in Next-Generation Sequencing , 2014, Molecular Diagnosis & Therapy.

[28]  Leslie Cope,et al.  Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. , 2014, American journal of clinical pathology.

[29]  Yibo Gao,et al.  Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[30]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[31]  Jesse S. Voss,et al.  Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. , 2012, Human pathology.

[32]  Alexander Dobrovic,et al.  Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase , 2012, Oncotarget.

[33]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[34]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[35]  A. Grigoriadis,et al.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.

[36]  Manuela Zucknick,et al.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Caligiuri,et al.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[40]  F. Pontén,et al.  A high frequency of sequence alterations is due to formalin fixation of archival specimens. , 1999, The American journal of pathology.

[41]  D. Brat,et al.  Research and applications: Cancer Digital Slide Archive: an informatics resource to support integrated in silico analysis of TCGA pathology data , 2013, J. Am. Medical Informatics Assoc..

[42]  Jeffrey W. Clark,et al.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. , 2012, The oncologist.

[43]  H. Armah.  Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas , 2010 .

[44]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2010, Nature.